Stock · MCK · Healthcare
United States · Large Cap · listed since 1994 · Revenue 12 mo. $411B
Price as of 11/06/2026
McKesson Corporation provides healthcare services in the United States and internationally.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Original text from the data provider
Summary
53.1 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €4.9B (2026), it supports €53.9B. The remaining €56.6B of the market value assume it grows 10.1% a year for 10 years and not at all afterwards.
Required FCF growth per year
10.1%
no growth afterwards
Price to operating cash flow 18.5×, above its usual range.
Middle half of 20 quarters: 10.1× to 14.6×, median 12.2×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q1 → Q2 2026
4 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, FCF margin
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | −265.44% | 11.52% | Rank 2 |
| Return on capital (Greenblatt) | 136.56% | 32.55% | Rank 96 |
| EBIT margin | 1.60% | 18.31% | Rank 9 |
| FCF margin | 1.34% | 14.12% | Rank 9 |
| Gross margin | 3.61% | 60.99% | Rank 1 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 12.36% | 8.04% | Rank 74 |
| Earnings growth, 3 years per year | 15.30% | 5.44% | Rank 69 |
| Earnings growth, 5 years per yeardoes not count towards the rank | – | 7.00% | |
| Sustainable growth (ROE × retained earnings) | 0.18% | 3.66% | Rank 5 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 3.62% | 2.90% | Rank 64 |
| FCF yield | 4.39% | 3.63% | Rank 60 |
| EV/saleslower is better | 0.32 | 4.03 | Rank 95 |
| EV/EBITlower is better | 19.81 | 21.73 | Rank 54 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 13.95% | 8.66% | Rank 57 |
| Share price, 6 months | 44.60% | 24.27% | Rank 82 |
| Share price, 3 months | 27.13% | 15.42% | Rank 84 |
| Distance from 52-week high | −1.04% | −7.35% | Rank 83 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 2.59% | 0.30% | Rank 30 |
| Change in share countlower is better | −3.12% | 0.00% | Rank 90 |
| Dividend streak in years | 26 | 10 | Rank 90 |
| Price reaction to results, market-adjusted | −0.42% | 0.05% | Rank 42 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | −2.64% | 48.40% | Rank 3 |
| Net debt/EBITDAlower is better | 0.65 | 1.11 | Rank 59 |
| Debt to equitylower is betterdoes not count towards the rank | −3.97 | 0.48 | |
| Volatility, 1 yearlower is better | 31.04% | 31.42% | Rank 54 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2017 | 198.5 | 1.7% | 4.2 | 223M | 5.8 |
| 2018 | 208.4 | 1.4% | 3.8 | 209M | 5.2 |
| 2019 | 214.3 | 1.4% | 3.5 | 197M | 4.6 |
| 2020 | 231.1 | 1.3% | 3.9 | 182M | 5.4 |
| 2021 | 238.2 | 1.5% | 3.9 | 161M | 3.1 |
| 2022 | 264.0 | 1.0% | 3.9 | 154M | 4.0 |
| 2023 | 276.7 | 1.6% | 4.6 | 142M | 2.6 |
| 2024 | 309.0 | 1.3% | 3.6 | 134M | 2.8 |
| 2025 | 359.1 | 1.2% | 5.2 | 128M | 1.7 |
| 2026 | 403.4 | 1.6% | 5.4 | 124M | 4.6 |
3 of 7 StockScorer Score rules met · How the score is built
McKesson Corporation mainly meets criteria in the Valuation category. Result from 18 strategies checked.
McKesson Corporation is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for McKesson Corporation.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 27.6 | 30.0 |
| P/B ratio | −56.4 | 4.8 |
| Return on equity (ROE) | −265.4% | 11.5% |
| Equity ratio | −2.6% | 48.4% |
| Debt-to-equity (D/E) | −3.97 | 0.48 |
| Dividend yield | 0.3% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| MCK | McKesson Corporationthis page | |
| COR | Cencora Inc. | Low4.5 |
| CAH | Cardinal Health Inc | Medium5.5 |
| SIG.AX | Sigma Healthcare Ltd | locked |
| HSIC | Henry Schein Inc | locked |
| M12.DE | M1 Kliniken AG | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.